QTRX — Quanterix Corporation

Quanterix Corporation (QTRX) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $36.4 million, a 20% increase year-over-year.
• Organic Revenue: Declined by 21%.
• Diagnostics Revenue: $2.9 million, up from $1.6 million in Q1 2025.
• Instrumentation Revenue: $4 million, with Simoa contributing $2.3 million and spatial $1.7 million.
• Gross Profit: $15.6 million, representing a gross margin of 42.7%. Non-GAAP gross profit was $18.5 million with a margin of 50.9%.
• Operating Expenses: $56.9 million, including $22 million related to acquisition and restructuring costs.
• Adjusted EBITDA: Loss of $9.8 million, an improvement of $1.5 million sequentially.
• Cash Position: Ended the quarter with $102.6 million in cash and equivalents, with a cash usage of $19 million.

2. Strategic Updates and Business Highlights

• Leadership Changes: New CEO Everett Cunningham emphasized a shift towards growth and operational execution, focusing on the Alzheimer's diagnostics market.
• Market Leadership: Quanterix remains a leader in early disease biomarker detection, with over 2,300 installed instruments.
• Investment in Alzheimer's Diagnostics: Plans to enhance the LucentAD Complete test and expand partnerships, including a new collaboration with Tempus AI.
• Operational Improvements: Initiatives to improve commercial effectiveness, including hiring lead generation representatives and enhancing marketing strategies.
• Product Development: Upgrading the Simoa HD-X platform for IVD status by 2027, focusing on reliability and market readiness.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Maintained at approximately $169 million to $174 million.
• Gross Margin Expectations: GAAP gross margin projected between 41% to 45%, and non-GAAP gross margin between 49% to 53%.
• Cash Flow Breakeven: Expected by Q4 2026, with a forecasted cash balance of around $100 million by year-end.
• Q2 Revenue Expectations: Anticipated to be in line or slightly ahead of Q1 results, with a stronger second half driven by commercial initiatives.

4. Bad News, Challenges, or Points of Concern

• Organic Revenue Decline: A significant 21% decline in organic revenue raises concerns about market demand and execution.
• Instrumentation Shortfall: Weaker-than-expected instrumentation revenue due to timing issues, which may impact future performance.
• Market Conditions: Ongoing challenges in end markets, particularly in the academic sector, which may affect growth.
• Dependency on Future FDA Approvals: The success of the Alzheimer's diagnostics business hinges on timely FDA clearance and market acceptance.

5. Notable Q&A Insights

• IVD Submission for HD-X: Cunningham explained the strategic importance of IVD status for the HD-X platform, emphasizing its role in both research and diagnostics.
• Focus on Pharma Partnerships: Acknowledged recent underperformance in the pharma sector but expressed confidence in upcoming improvements due to new leadership and strategic focus.
• Market Conditions: Management does not expect significant market improvements but is focusing on internal actions to drive growth.
• Clinical Utility Studies: Upcoming studies are crucial for demonstrating the effectiveness of the LucentAD Complete test, with results expected in the second half of 2026.

This summary encapsulates Quanterix's current financial standing, strategic direction, future outlook, and challenges faced, providing a balanced view of the company's performance and prospects.